event
Special Biochem Seminar: Prof. Berkley Gryder (Case Western Reserve University)
Primary tabs
Technical Abstract:
Androgen Receptor (AR) amplification during relapse is a central driver of metastatic castration-resistant prostate cancer (mCRPC). Antagonists of the AR fail to benefit these mCRPC patients who have dramatic increases in AR expression. Inverse agonists functionally switch hormone receptors from activators to repressors of their target genes, but inverse agonists of the AR have not yet been identified. We designed the first AR inverse agonists (ARIA). Mechanistically, these inverse agonists bind the ligand-binding domain of the AR, cause AR nuclear localization, elicit recruitment of co-repressors to AR response elements, and reconfigure chromatin by reducing histone acetylation. ARIA treatment causes the collapse of loops between enhancers and promoters at key genes in the AR-driven epigenome. Transcription of AR target genes, such as KLK3 (encoding Prostate Specific Antigen, PSA), is potently and selectively reduced. The ARIA BG-15a and the pharmacokinetically optimized BG-15n are orally available and reduce tumor growth in antagonist-resistant in vitro and in vivo models of mCRPC. ARIA therapeutics represents a promising new strategy for treating patients with relapsed AR-driven mCRPC tumors.
Groups
Status
- Workflow Status:Published
- Created By:Michele Yager
- Created:09/01/2022
- Modified By:Michele Yager
- Modified:09/05/2022
Categories
Keywords
Target Audience